Should I Buy SBRA? SBRA 2026 Analysis

Should You Buy Sabra Health Care REIT Inc (SBRA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

18.450

1 Day change

-0.32%

52 Week Range

19.970

Analysis Updated At

2026/01/26

Sabra Health Care REIT Inc (SBRA) is not a strong buy for a beginner investor with a long-term strategy at this moment. While the stock has some positive long-term potential, the lack of strong technical signals, declining financial performance, and neutral sentiment from hedge funds and insiders suggest waiting for a better entry point.

Technical Analysis

The MACD is negative and expanding (-0.0533), indicating bearish momentum. RSI is neutral at 30.652, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 18.885), with resistance at R1: 19.664. Overall, technical indicators suggest a weak trend.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low Put-Call Ratios indicate a slightly bullish sentiment, but the implied volatility percentile (95.6) is high, suggesting elevated uncertainty.

Technical Summary

Sell

Buy

Positive Catalysts

Analysts see potential upside in the REIT's SHOP segment and a favorable supply/demand backdrop. Healthcare REITs are expected to benefit from demographic tailwinds.

Neutral/Negative Catalysts

The company's financial performance in Q3 2025 showed declining net income (-24.34% YoY), EPS (-30.77% YoY), and gross margin (-6.08% YoY). Analysts note that occupancy and cash NOI margins are still below pre-COVID levels. Hedge funds and insiders are neutral, and there is no recent congress trading data.

Financial Performance

In Q3 2025, revenue increased by 6.76% YoY to $190.037M, but net income dropped by 24.34% YoY to $22.538M. EPS fell by 30.77% YoY to 0.09, and gross margin declined to 65.3%. This reflects a mixed financial performance with growth in revenue but significant declines in profitability metrics.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is mixed. Truist and UBS maintain Neutral ratings with price targets of $20-$21, citing improving fundamentals but limited valuation upside. Jefferies and Wells Fargo are more optimistic, with price targets of $21-$22 and Overweight/Buy ratings, highlighting potential in the SHOP segment and favorable demand-supply dynamics.

7 Analyst Rating

Wall Street analysts forecast SBRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SBRA is 20.83 USD with a low forecast of 20 USD and a high forecast of 22 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

4 Hold

0 Sell

Moderate Buy

Current: 18.510

Low

Averages

20.83

High

Current: 18.510

Low

Averages

20.83

High

Truist

Michael Lewis

Hold

maintain

$20 -> $21

AI Analysis

2026-01-20

Reason

Truist

Michael Lewis

Price Target

$20 -> $21

AI Analysis

2026-01-20

maintain

Hold

Reason

Truist analyst Michael Lewis raised the firm's price target on Sabra Health Care to $21 from $20 and keeps a Hold rating on the shares. The firm adjusted ratings and targets in the real estate investment trust group as part of its 2026 outlook. Truist remains Neutral on REITs for 2026, saying fundamentals are improving as new supply slows and demand appears steady for high-quality assets. However, the stocks do not appear particularly cheap, the analyst tells investors in a research note. Truist is relatively bullish on healthcare, industrial, strip retail, gaming and lodging REITs, neutral on manufactured housing, multifamily, self-storage and triple net, and relatively cautious on mall and office.

Jefferies

Joe Dickstein

Buy

maintain

$21 -> $22

2025-12-15

Reason

Jefferies

Joe Dickstein

Price Target

$21 -> $22

2025-12-15

maintain

Buy

Reason

Jefferies analyst Joe Dickstein raised the firm's price target on Sabra Health Care to $22 from $21 and keeps a Buy rating on the shares as part of a broader research note previewing 2026 for Healthcare REITs. The firm expects another challenging year for lab landlords as elevated market vacancy and a 9.6% decline in trailing-12-month biotech funding will drive below-average retention in 2026, the analyst tells investors in a research note. For Sabra, Jefferies sees upside embedded in the REIT's SHOP segment while also noting that occupancy and cash net operating income margin are still materially below pre-COVID levels, while supply/demand backdrop is "very attractive".

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SBRA

Unlock Now

SBRA Should I Buy

SBRA Should I Buy

Should You Buy Sabra Health Care REIT Inc (SBRA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch